Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · Children with recurrent abdominal pain
1 finding from 1 review
Improvement in pain: 0 to 3 months' postintervention Improvement in pain was defined and measured differently in the 2 included studies: using a "stomach ache diary" and the Faces Pain Scale (Bieri 1990). · Children with recurrent abdominal pain
Fibre showed no clear difference in improvement in pain: 0 to 3 months' postintervention Improvement in… compared with placebo (low certainty).
1 finding from 1 review
Pain duration (mean pain duration, assessed at 4 weeks) · Children with recurrent abdominal pain
It is very uncertain whether antispasmodics changes pain duration (mean pain duration, assessed at 4 weeks) compared with placebo (very low certainty).
1 finding from 1 review
Pain improvement (clinician judged, assessed at 2 weeks) · Children with recurrent abdominal pain
It is very uncertain whether antispasmodics changes pain improvement (clinician judged, assessed at 2 weeks) compared with placebo (very low certainty).
1 finding from 1 review
Pain episodes · Children with recurrent abdominal pain
It is very uncertain whether antispasmodics changes pain frequency (episodes of pain in 4 weeks, assessed after 4 weeks) compared with placebo (very low certainty).
1 finding from 1 review
Pain improvement (self reported response to treatment, assessed at 4 weeks) · Children with recurrent abdominal pain
Antispasmodics showed no clear difference in pain improvement (self reported response to treatment, assessed at 4… compared with placebo (low certainty).
1 finding from 1 review
Inattention Measured using SNAP‐IV inattention subscale (range 0 to 27) · Children aged 6 to 18 years with ASD
2 findings from 1 review
Impulsivity · Children aged 6 to 18 years with ASD
2 findings from 1 review
Hyperactivity · Children aged 6 to 18 years with ASD
2 findings from 1 review
Impaired social interaction · Children aged 6 to 18 years with ASD
2 findings from 1 review
Impaired communication · Children aged 6 to 18 years with ASD
2 findings from 1 review
Stereotypical behaviours · Children aged 6 to 18 years with ASD
2 findings from 1 review
Overall ASD · Children aged 6 to 18 years with ASD
2 findings from 1 review
Total number of adverse events · Children aged 6 to 18 years with ASD
2 findings from 1 review
Reduction in crying duration Difference between final values (hours per day of crying) · infants with colic defined by recognised criteria
It is very uncertain whether simethicone changes reduction in crying duration Difference between final values (hours… compared with placebo (very low certainty).
1 finding from 1 review
Responders Number of infants who improved after treatment · infants with colic defined by recognised criteria
Simethicone showed no clear difference in responders Number of infants who improved after treatment compared with placebo (low certainty).
1 finding from 1 review
Reduction in crying duration Difference before and after treatment (hours per day of crying) · patients with infantile colic
Herbal agents may leads to higher reduction in crying duration Difference before and after treatment… compared with placebo (low certainty).
1 finding from 1 review
Responders Number of infants who improved after treatment · patients with infantile colic
Herbal agents probably leads to higher responders Number of infants who improved after treatment compared with placebo (moderate certainty).
1 finding from 1 review
Reduction in crying duration Difference before and after treatment (hours per day of crying) · infants with colic defined by recognised criteria
It is very uncertain whether sugar changes reduction in crying duration Difference before and after treatment… compared with placebo (very low certainty).
1 finding from 1 review
Reduction in crying duration Difference between final values (minutes per crisis of crying) · infants with colic defined by recognised criteria
It is very uncertain whether cimetropium bromide changes reduction in crying duration Difference between final values… compared with placebo (very low certainty).
1 finding from 1 review